Navigation Links
Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
Date:3/13/2008

------------- -------------

Forward Looking Statements

--------------------------

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; decisions, and the timing of decisions, made by health regulatory agen
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
2. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
3. Angiotech announces results for the fourth quarter ended December 31, 2007
4. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
6. Angiotech and Symphony Medical Announce Licensing Agreement
7. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech to participate in Bank of America 2007 Credit Conference
11. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... -- Origin Agritech Limited (NASDAQ GS: SEED) (" Origin ", or ... in China , today announced that the ... September 30, 2014, before the market opens on Thursday, January ... on January 8, 2015, at 8:00 a.m. ET / 9:00 ... results. To participate in the call, please dial +1-888-346-8982 in ...
(Date:12/13/2014)... N.C. (PRWEB) December 13, 2014 CanDiag, ... Charlotte) spin-out company has changed its name to OncoTab, ... accurate representation of where we are today,” said CEO ... extended our platform’s applications beyond breast cancer diagnostics to ... a reflection of that evolution.” , Founded in 2011 ...
(Date:12/13/2014)... 2014 Clarassance, a privately held clinical-stage ... name: Therabron Therapeutics , Inc. The new name ... type of structure in the lungs similar to branches ... develop novel protein therapeutics for the treatment of respiratory ... change the name to mark the company's escalation into ...
(Date:12/13/2014)... 12, 2014 Trend lines for photonics ... global economic growth, Eugene Arthurs, CEO of SPIE, ... in a featured talk at OPTIC (Optics and Photonics ... National Chung Hsing University in Taichung. , As examples, ... future energy supplies and soon to hit US$50 billion ...
Breaking Biology Technology:Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5
... create the largest non-state-owned producers of ... plasma-based product in China, ... Inc. (OTC Bulletin Board: CBPO) ("China Biologic" or the,"Company"), one ... China ("PRC"), today announced that on September 26,2008, the Company ...
... LIVINGSTON, N.J., Oct. 2 Milestone Scientific,Inc. ... in advanced,injection technologies, today announced that it ... painless anesthetic injections --,specifically rights related to ... providing these injections -- through issuance of ...
... Radioimmunotherapy in U.S. to be Indicated ... for Use in First-Line ... and MTA: CTIC) announced today that it has submitted a ... (FDA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as,consolidation therapy after ...
Cached Biology Technology:China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 2China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 3China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 4China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 5Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations 2Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
(Date:11/18/2014)... 2014   News Highlights: ... develop The Partners Data Lake, an agile data ... Lake will allow researcher and clinicians to explore ... the lives of patients , The Partners ... across the Partners system, breaking down physical barriers ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... is perhaps impossible to overstate the importance of the tumor ... gene in human tumors. p53 keeps pre-cancerous cells in check ... aging at the cellular level. Loss of p53 causes cells ... or damaged cells die or stop growing. In ...
... This press release is available in Spanish . ... U.S. Department of Agriculture (USDA) scientists are learning more ... fieldsand whether they,ll actively feed on crop pests. ... the North Central Agricultural Research Laboratory in Brookings, S.D., ...
... in sustained tissue damage in the brains and spines of ... reveal. Cytoxic T cells, also known as CD8+ T ... body,s arsenal to fight disease. Multiple sclerosis is characterized ... and destroy the axons, electrical impulse conductors that look like ...
Cached Biology News:Cancer suppressor gene links metabolism with cellular aging 2Cancer suppressor gene links metabolism with cellular aging 3Lady beetle diet influences its effectiveness as biocontrol agent 2Multiple sclerosis study reveals how killer T cells learn to recognize nerve fiber insulators 2Multiple sclerosis study reveals how killer T cells learn to recognize nerve fiber insulators 3Multiple sclerosis study reveals how killer T cells learn to recognize nerve fiber insulators 4
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated ...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Biology Products: